Nasdaq:US$13.46 (-0.33) | HKEX:HK$21.32 (-0.26) | AIM:£1.94 (-0.07)
Search
EN
简
繁
About Us
Overview
Corporate Information
Board of Directors
Leadership
Sustainability
Contact Us
What We Do
Overview
Research and Development
Commercialization in China
Other Ventures
Key Corporate Partnerships
Pipeline & Products
Overview
Our Products
Our Pipeline
Expanded Access
News & Publications
News & Press Releases
Scientific Publications
Mailing List Sign-up
Shareholder Information
Overview
Announcements
Events, Presentations & Circulars
Share Price & Chart
Major Shareholders
Financial Reports & Filings
Analyst Coverage
Listing FAQs for Shareholders
Information for Shareholders
Corporate Governance
AIM Rule 26
Dissemination of Corporate Communications
Modern Slavery and Human Trafficking Statement
Career
About Us
Overview
Corporate Information
Board of Directors
Leadership
Sustainability
Contact Us
What We Do
Overview
Research and Development
Commercialization in China
Other Ventures
Key Corporate Partnerships
Pipeline & Products
Overview
Our Products
Our Pipeline
Expanded Access
News & Publications
News & Press Releases
Scientific Publications
Mailing List Sign-up
Shareholder Information
Overview
Announcements
Events, Presentations & Circulars
Share Price & Chart
Major Shareholders
Financial Reports & Filings
Analyst Coverage
Listing FAQs for Shareholders
Information for Shareholders
Corporate Governance
AIM Rule 26
Dissemination of Corporate Communications
Modern Slavery and Human Trafficking Statement
Career
News & Presentations
Hutchmed
| News & Presentations
News & Press Releases
3 Sep 2026
HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy
Read more
31 Aug 2026
HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS
®
Plus TAGRISSO
®
in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China
Read more
28 Aug 2026
HUTCHMED Announces NMPA Approval for ATLED
®
(Fanregratinib) for the Treatment of Patients with FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma
Read more
17 Aug 2026
HUTCHMED Announces ORPATHYS
®
Plus TAGRISSO
®
Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO
®
Read more
Scientific Publications
2 Jun 2026
Nature Medicine: Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial
Read more
24 Jan 2026
THE LANCET: Savolitinib plus osimertinib for advanced, EGFR mutation-positive, MET-amplified NSCLC in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial
Read more
13 Jan 2025
Targeted Oncology: Fruquintinib Plus Sintilimab in Patients with Treatment-Naive and Previously Treated Advanced Renal Cell Carcinoma: Results from a Phase Ib/II Clinical Trial
Read more
9 Jan 2025
THE LANCET Haematology: Sovleplenib in patients with primary or secondary warm autoimmune haemolytic anaemia: results from phase 2 of a randomised, double-blind, placebo-controlled, phase 2/3 study
Read more
Mailing List Sign-up
If you would like to be kept up to date with the latest news of HUTCHMED, please sign up to our mailing list . We will deliver the relevant material directly to your email box as soon as it becomes available online.